Scarica l'app Stockscreener
7.27
6.44%
-0.50
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$7.77
Aprire:
$7.44
Volume 24 ore:
1.13M
Relative Volume:
0.94
Capitalizzazione di mercato:
$197.41M
Reddito:
$157.75M
Utile/perdita netta:
$-29.73M
Rapporto P/E:
-6.2672
EPS:
-1.16
Flusso di cassa netto:
$-21.00M
1 W Prestazione:
-16.63%
1M Prestazione:
-65.79%
6M Prestazione:
-32.93%
1 anno Prestazione:
-60.36%
Intervallo 1D:
$7.26
$7.65
Intervallo di 1 settimana:
$7.26
$9.29
Portata 52W:
$7.26
$24.17
Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile
Nome
Arcturus Therapeutics Holdings Inc
Settore
Industria
Telefono
(858) 900-2660
Indirizzo
10285 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Confronta ARCT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARCT
Arcturus Therapeutics Holdings Inc
|
7.27 | 220.77M | 157.75M | -29.73M | -21.00M | -1.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
437.15 | 110.25B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
693.50 | 73.04B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.16 | 59.98B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
907.98 | 54.90B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.22 | 40.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-10-23 | Downgrade | Citigroup | Buy → Neutral |
| 2025-10-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2025-09-04 | Ripresa | H.C. Wainwright | Buy |
| 2025-05-28 | Iniziato | Scotiabank | Sector Outperform |
| 2025-01-28 | Iniziato | BTIG Research | Buy |
| 2024-08-12 | Iniziato | Leerink Partners | Outperform |
| 2023-12-13 | Iniziato | Canaccord Genuity | Buy |
| 2023-07-24 | Iniziato | William Blair | Outperform |
| 2023-05-11 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2022-11-14 | Ripresa | Wells Fargo | Overweight |
| 2022-11-10 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2022-11-03 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-11-02 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2022-08-10 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2022-07-19 | Ripresa | Cantor Fitzgerald | Overweight |
| 2022-05-11 | Aggiornamento | Robert W. Baird | Underperform → Neutral |
| 2022-04-21 | Downgrade | Citigroup | Buy → Neutral |
| 2022-01-31 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2021-08-12 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2021-08-11 | Downgrade | Goldman | Neutral → Sell |
| 2021-08-10 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2021-07-02 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-06-25 | Ripresa | Goldman | Neutral |
| 2021-06-21 | Downgrade | Barclays | Equal Weight → Underweight |
| 2021-06-04 | Ripresa | Robert W. Baird | Neutral |
| 2021-02-17 | Downgrade | B. Riley Securities | Neutral → Sell |
| 2021-01-19 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2021-01-15 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2021-01-07 | Iniziato | Wells Fargo | Overweight |
| 2020-12-29 | Downgrade | Barclays | Overweight → Equal Weight |
| 2020-12-29 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-12-29 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-12-29 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-12-23 | Downgrade | ROTH Capital | Buy → Sell |
| 2020-12-08 | Reiterato | B. Riley Securities | Buy |
| 2020-12-07 | Reiterato | B. Riley Securities | Buy |
| 2020-10-26 | Iniziato | Barclays | Overweight |
| 2020-10-06 | Iniziato | Citigroup | Buy |
| 2020-08-26 | Iniziato | Piper Sandler | Overweight |
| 2020-07-30 | Ripresa | ROTH Capital | Buy |
| 2020-07-16 | Iniziato | Raymond James | Outperform |
| 2020-07-13 | Iniziato | B. Riley FBR | Buy |
| 2020-06-09 | Downgrade | WBB Securities | Buy → Hold |
| 2020-02-11 | Iniziato | Robert W. Baird | Outperform |
| 2020-02-07 | Iniziato | Guggenheim | Buy |
| 2020-02-06 | Iniziato | Guggenheim | Buy |
| 2019-04-05 | Iniziato | H.C. Wainwright | Buy |
| 2018-09-20 | Aggiornamento | WBB Securities | Buy → Strong Buy |
| 2018-01-22 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Arcturus Therapeutics Holdings Inc Borsa (ARCT) Ultime notizie
Wall Street Zen Upgrades Arcturus Therapeutics (NASDAQ:ARCT) to “Hold” - Defense World
Published on: 2025-11-15 17:06:19 - newser.com
Can momentum traders help lift Arcturus Therapeutics Holdings Inc.Gold Moves & Detailed Earnings Play Alerts - newser.com
What technical models suggest about Arcturus Therapeutics Holdings Inc.’s comeback2025 Market Outlook & Momentum Based Trading Signals - newser.com
Arcturus Therapeutics Holdings Inc. stock volume spike explained2025 EndofYear Setup & High Accuracy Trade Alerts - newser.com
How to forecast Arcturus Therapeutics Holdings Inc. trends using time seriesJuly 2025 Market Mood & Technical Pattern Recognition Alerts - newser.com
Can Arcturus Therapeutics Holdings Inc. stock beat market expectations this quarter2025 Investor Takeaways & Verified Momentum Stock Alerts - newser.com
Arcturus Therapeutics Hits New 52-Week Low at $7.76 - Markets Mojo
What is William Blair’s Forecast for ARCT FY2025 Earnings? - Defense World
Published on: 2025-11-13 18:13:53 - newser.com
How to use a screener to detect Arcturus Therapeutics Holdings Inc. breakoutsJuly 2025 Recap & Precise Swing Trade Alerts - newser.com
Citigroup Maintains Arcturus Therapeutics Holdings (ARCT) Neutral Recommendation - Nasdaq
Arcturus outlines 12-week cystic fibrosis study launch in 2026 amid cost controls and delayed KOSTAIVE BLA - MSN
ARCT: Citigroup Adjusts Price Target and Maintains Neutral Ratin - GuruFocus
Is Arcturus Therapeutics Holdings Inc. stock cheap at current valuation2025 Technical Patterns & Real-Time Volume Analysis Alerts - newser.com
What MACD signals say about Arcturus Therapeutics Holdings Inc.Rate Hike & AI Powered Buy and Sell Recommendations - newser.com
How currency fluctuations impact Arcturus Therapeutics Holdings Inc. stockOil Prices & Weekly Top Gainers Trade List - newser.com
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q3 2025 Earnings Call Transcript - Insider Monkey
Arcturus Therapeutics Holdings Inc. SEC 10-Q Report - TradingView
ARCT: HC Wainwright & Co. Lowers Price Target, Maintains Neutral Rating | ARCT Stock News - GuruFocus
Understanding the Setup: (ARCT) and Scalable Risk - news.stocktradersdaily.com
HC Wainwright & Co. Maintains Arcturus Therapeutics Holdings (ARCT) Neutral Recommendation - Nasdaq
Arcturus Therapeutics (ARCT) Target Price Significantly Lowered by Piper Sandler | ARCT Stock News - GuruFocus
Arcturus Therapeutics Holdings Inc earnings missed by $6.02, revenue fell short of estimates - Investing.com Australia
Published on: 2025-11-11 06:27:18 - newser.com
Arcturus Therapeutics (ARCT) Reports Q3 Loss, Beats Revenue Estimates - sharewise.com
Arcturus Therapeutics Holdings Inc (ARCT) Q3 2025 Earnings Call Highlights: Navigating ... By GuruFocus - Investing.com Canada
Arcturus Therapeutics (ARCT) Reports Q3 2025 Earnings and Clinical Updates - GuruFocus
Arcturus Therapeutics Holdings Inc (ARCT) Q3 2025 Earnings Call Highlights: Navigating ... - Yahoo Finance
Arcturus Therapeutics Reports Q3 2025 Financials and Pipeline Progress - TipRanks
What analysts say about Arcturus Therapeutics Holdings Inc stockStock Market Trends & Low Entry Investment Portfolio - earlytimes.in
Earnings call transcript: Arcturus Therapeutics’ Q3 2025 Earnings Miss Expectations - Investing.com
Arcturus Therapeutics Announces Third Quarter 2025 Financial Update and Pipeline Progress - BioSpace
INVESTIGATION ALERT: Edelson Lechtzin LLP Announces Investigation of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) and Encourages Investors with Substantial Losses to Contact the Firm - The Malaysian Reserve
Earnings call transcript: Arcturus Therapeutics’ Q3 2025 Earnings Miss Expectations By Investing.com - Investing.com UK
Arcturus Therapeutics Q3 2025 Earnings Call Transcript - MarketBeat
Arcturus Therapeutics (ARCT) Exceeds Q3 Revenue Expectations - GuruFocus
Arcturus Therapeutics: Q3 Earnings Snapshot - MarketScreener
What candlestick patterns are forming on Arcturus Therapeutics Holdings Inc.Market Movers & Safe Entry Point Alerts - newser.com
Arcturus Therapeutics Hits 52-Week Low at $7.93 Amid Financial Struggles - Markets Mojo
What is Arcturus Therapeutics Holdings Inc (ARCT) Stock Return on Shareholders’ Capital? - setenews.com
Is Arcturus Therapeutics Holdings Inc. stock ready for a breakoutGlobal Markets & Technical Buy Zone Confirmations - newser.com
Arcturus Therapeutics Holdings Inc Azioni (ARCT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.43%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):